Optomed
Optomed is a Finnish medical technology company that develops handheld and desktop fundus cameras with integrated AI software for retinal screening, serving primary care, screening programs, optometry, emergency/neurology, pediatrics, and veterinary customers across more than 60 countries.
- Company typePublic
- Founded1999
- HeadquartersOulu, Finland
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Optomed does
Optomed Oyj is a Finnish medical technology company that develops and sells handheld and desktop fundus cameras combined with AI-powered software for retinal screening and diagnosis. Founded in 1999 and headquartered in Oulu, Finland, the company listed on Nasdaq Helsinki in December 2019 and operates in over 60 countries with approximately 100 employees. Its hardware lineup includes the Optomed Lumo, Aurora IQ, Aurora AEYE, and Smartscope PRO handheld cameras plus the Polaris desktop camera, all leveraging proprietary optics (High-Contrast Optical Design, Smart Autofocus), non-mydriatic imaging, wireless DICOM connectivity, and AES-256 encryption. The software stack centers on the Avenue suite (Eye Screen, Flow, AI, Telemedicine), with the Avenue AI gateway integrating multiple validated AI algorithms for diabetic retinopathy and other ocular disease detection.
The company reports two segments. The Devices segment generated EUR 7.6M in FY2025 (+43.1% YoY), while the Software segment generated EUR 9.5M (-2.5% YoY), for total revenue of EUR 17.1M (+13.7% YoY versus EUR 15.0M in 2024). Go-to-market combines direct enterprise sales, distribution partners, OEM integrations, and a U.S. screening-services distributor; target end markets include primary care, population screening programs, optometry, emergency/neurology eye triage, pediatrics, and veterinary applications. Optomed holds 50+ technology patents, FDA/CE-MDR/CFDA medical device clearances, and ISO 13485 and ISO 27001 certifications.
Despite mid-teens revenue growth, the company remains unprofitable, posting FY2025 EBITDA of EUR -3.5M (margin -20.6%, improved from -23.0% in 2024) and a net loss of EUR -6.6M. Growth has been funded via directed share issues totaling EUR 13.9M in 2024-2025 on top of the EUR 20M IPO proceeds in 2019, with stated use of funds for AI development and U.S. commercialization following the FDA clearance of the Aurora AEYE.
Optomed firmographics
Firmographics- Name
- Optomed
- Legal name
- Optomed Oyj
- Website
- https://optomed.com
- Company type
- Public
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Optomed is a Finnish medical technology company that develops handheld and desktop fundus cameras with integrated AI software for retinal screening, serving primary care, screening programs, optometry, emergency/neurology, pediatrics, and veterinary customers across more than 60 countries.
- Ownership category
- akta.pro rank
Optomed industry classification
Industry- Product category
- Medical Imaging Devices (Ophthalmic / Retinal Imaging)
- NAICS
- Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)
- akta.pro primary industry
- Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)
- akta.pro secondary industry
- Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where Optomed is headquartered
LocationHeadquarters
- HQ city
- Oulu
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
Optomed business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- Devices Segment: Handheld fundus cameras and related hardware sales. Revenue EUR 7.6 million in 2025, representing 43.1% year-over-year growth. Includes Optomed Lumo, Aurora IQ, Aurora AEYE, Smartscope PRO, and Polaris cameras.
- Software Segment: AI-powered screening software and telemedicine solutions. Revenue EUR 9.5 million in 2025, representing 2.5% decline. Includes Avenue Eye Screen, Avenue Flow, Avenue AI, and Avenue Telemedicine.
- Device Sales (One-time): One-time device orders from distributors, evidenced by EUR 1.8 million order from U.S. screening service provider without recurring AI services.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Enterprise/hardware pricing through direct sales and distributors |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Optomed product offering
Product offeringCore offering
Optomed designs, manufactures, and sells handheld and desktop fundus cameras for retinal imaging, paired with AI-powered screening software (the Avenue suite) for point-of-care diabetic retinopathy screening and ophthalmic workflows. The integrated device-plus-AI platform is sold to primary care clinics, screening programs, optical retailers, emergency departments, pediatric settings, and veterinary clinics globally.
Product overview
Optomed offers a comprehensive portfolio of medical imaging products centered on handheld and desktop fundus cameras for retinal imaging and diabetic retinopathy screening. The core product line includes the Optomed Lumo, Aurora IQ, Aurora AEYE, Smartscope PRO, and Polaris cameras. These hardware products are complemented by the Avenue software suite, which provides AI-powered diagnostic capabilities (Avenue Eye Screen, Avenue AI), workflow management (Avenue Flow), and telemedicine functionality (Avenue Telemedicine). Additional solutions extend to radiology, cancer screening, cephalometry, and pathology. The platform integrates with standard medical imaging infrastructure including DICOM and PACS systems for deployment in healthcare environments.
Differentiator
Problem solved
Functional benefit
Brands
- Optomed Lumo: Portable non-mydriatic retinal camera with AI integration for point-of-care screening
- Optomed Aurora IQ
- Optomed Aurora AEYE
- Smartscope PRO
- Optomed Polaris
- Avenue AI
- Avenue Telemedicine
- Avenue Eye Screen
- Avenue Flow
Products and services
- Optomed Lumo Handheld fundus camera with integrated wireless DICOM connectivity and AI-powered diabetic retinopathy screening capabilities for primary care and screening program deployment.
- Optomed Aurora IQ Handheld fundus camera offering high-quality retinal imaging for diabetic retinopathy screening, general ophthalmology applications, and veterinary use in various clinical settings.
- Optomed Aurora AEYE Handheld fundus camera with integrated AI analysis for automated diabetic retinopathy detection, combining hardware capture with AI-powered diagnostic capabilities in a single device.
- Smartscope PRO Handheld fundus camera designed for retinal imaging in clinical and screening applications, providing portable fundus photography capabilities.
- Optomed Polaris Desktop fundus camera offering high-resolution retinal imaging for comprehensive eye examinations and diagnostic applications in ophthalmology practices.
- Avenue Eye Screen AI-powered ophthalmology screening solution that integrates with Optomed fundus cameras to provide automated diabetic retinopathy detection and screening workflow management.
- Avenue Flow Ophthalmology workflow management module that streamlines screening processes, patient data handling, and integrates with electronic health record systems for comprehensive eye care programs.
- Avenue AI Artificial intelligence gateway platform that enables integration of multiple AI-powered diagnostic tools into clinical ophthalmology workflows, providing a unified interface for AI-assisted diagnosis.
- Avenue Telemedicine Telemedicine solution enabling remote eye screening consultations, allowing healthcare providers to conduct virtual eye examinations and share diagnostic data securely.
Quantifiable outcome
- Devices segment grew 43.1% year-over-year in 2025
- +3 more outcomes
Companies that use Optomed
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles4 records
Optomed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature8 records
Optomed partnerships and signals
Strategic signalScale indicators10 records
Recent moves7 records
Expansion highlights6 records
Optomed competitors and assessment
Company assessmentDirect peers
- Topcon Healthcare: Japanese ophthalmic device manufacturer with extensive fundus camera, OCT, and screening product lines. Direct peer competing in the same primary-care and screening segments with both handheld and tabletop retinal imaging systems.
- Nidek: Japanese ophthalmic equipment company producing fundus cameras, OCT, and laser systems. Direct peer competing for the same optometry and ophthalmology customer base, particularly in Asia and Europe.
- Heidelberg Engineering: German manufacturer of OCT, fundus imaging, and confocal laser ophthalmoscopy systems. Direct peer in ophthalmic diagnostic imaging with strong presence in specialty and screening practices.
- Kowa Company (Ophthalmic): Japanese manufacturer of fundus cameras and ophthalmic diagnostic equipment. Direct peer with comparable handheld and tabletop retinal imaging offerings, particularly strong in Asian markets.
Emerging players
- Eyenuk: U.S. AI health company developing EyeArt autonomous diabetic retinopathy screening. Emerging peer in the AI diabetic retinopathy detection space where Optomed's Aurora AEYE and Avenue AI compete.
- AEYE Health: AI diagnostic company whose algorithm is integrated into Optomed's Aurora AEYE handheld fundus camera. Both partner and emerging competitor in the AI diabetic retinopathy space, representing the partner-network model Avenue AI is built around.
- Digital Diagnostics: U.S. company that received FDA De Novo clearance for IDx-DR, the first autonomous AI diagnostic system for diabetic retinopathy. Emerging peer in autonomous diabetic retinopathy screening that Optomed's Aurora AEYE competes against in primary care.
Broad incumbents
- Carl Zeiss Meditec: German-listed global leader in ophthalmic devices including fundus cameras, OCT, and surgical microscopes. Directly comparable as Optomed's primary large-scale competitor in retinal imaging, but with a much broader portfolio (surgical, laser, IOL) and substantially larger resources.
- Canon Medical Systems (Ophthalmic): Division of Canon producing retinal imaging cameras (CR-2, CX-1) for ophthalmology and screening. Direct competitor in the fundus camera category but embedded within a much larger medical imaging conglomerate.
Regional players
- iCare (Revenio Group): Finnish-listed medtech company producing handheld tonometers and ocular diagnostics. Regional peer with similar handheld diagnostic device DNA, though focused on intraocular pressure rather than retinal imaging.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Optomed social profiles
Digital presenceOptomed compliance and trust
Trust signalCompliance5 records
Optomed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Optomed leadership team
Management profileNumber of profiles
Profiles4 records
Optomed subsidiaries and ownership
Company hierarchySubsidiaries1 record
Optomed funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Optomed M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Optomed
What does Optomed do?
Optomed designs, manufactures, and sells handheld and desktop fundus cameras for retinal imaging, paired with AI-powered screening software (the Avenue suite) for point-of-care diabetic retinopathy screening and ophthalmic workflows. The integrated device-plus-AI platform is sold to primary care clinics, screening programs, optical retailers, emergency departments, pediatric settings, and veterinary clinics globally.
Is Optomed a public or private company?
Optomed is a public company. It is classified as public and is currently operating.
When was Optomed founded?
Optomed was founded in 1999. It employs 101 to 250 people.
Where is Optomed based?
Optomed is headquartered in Oulu, Finland, in the Europe region.
How does Optomed make money?
Three revenue lines are on record. Devices Segment is the primary driver. The others are software Segment and device Sales (One-time).
Who are Optomed's main competitors?
Direct peers on record are Topcon Healthcare, Nidek, Heidelberg Engineering and Kowa Company (Ophthalmic). Emerging players are Eyenuk, AEYE Health and Digital Diagnostics. Broad incumbents are Carl Zeiss Meditec and Canon Medical Systems (Ophthalmic). iCare (Revenio Group) is listed as a regional player.
Does Optomed have an API?
No public API is recorded for Optomed.
What industry is Optomed in?
Optomed's product category is Medical Imaging Devices (Ophthalmic / Retinal Imaging). Its primary akta.pro industry code is HLAHAJAC, Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity), with a secondary code of HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging). Its NAICS code is 339115 and its SIC code is 3841.